Barr Sued Over Plan For Schizophrenia Drug
Otsuka filed the lawsuit in response to Barr’s abbreviated new drug application, filed in November with the U.S. Food and Drug Administration. The ANDA, which seeks permission to make the generic version, claims Otsuka’s patent for Abilify is invalid.
The lawsuit was filed on March 16 with the U.S. District Court for the District of New...
To view the full article, register now.